NASDAQFinancialsFinancial Data & Stock ExchangesSnapshot 2026-07-31
Reading CME? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 5% over the past year and decelerating.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCME's growth in revenue and earnings is supported by strong product expansion. Recent earnings beat expectations, indicating strong revenue potential. It trades at 22.6× P/E versus a peer median of 12.2×. This suggests the price reflects modest growth compared to our view. A specific risk is the 12% probability of a miss in the next quarter. Peer multiples imply a price about 10% below where it trades. Our read remains intact.
Trailing returns as of 2026-07-31. CME is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering CME (as of Jul 2026).
Based on 5 Wall Street analysts offering 12-month price targets for CME in the last 4 months.
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Financial Exchanges & Data — fair value, gap to price, and forward P/E.
Advances: Expand product offerings and market access
New product offerings enhance market access and growth potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $267.79
The last 12 months of price, then the range of analyst 12-month targets from today’s $267.79.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Expand product offerings and market access
New product offering enhances market access and trading volume.
Advances: Achieve record revenue and earnings
Earnings beat indicates strong revenue growth potential.
Advances: Achieve record revenue and earnings
Earnings call highlights indicate strong revenue growth.
Advances: Expand product offerings and market access
New products expand offerings and market access.
Threatens: Expand product offerings and market access
CFTC's block impacts product expansion plans.
Advances: Expand product offerings and market access
New futures contracts expand product offerings significantly.
Threatens: Increase average daily trading volume (ADV)
Weaker trading volumes impact average daily trading volume objective.
